1. Home
  2. MHF vs PLYX Comparison

MHF vs PLYX Comparison

Compare MHF & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Municipal High Income Fund Inc.

MHF

Western Asset Municipal High Income Fund Inc.

N/A

Current Price

$6.42

Market Cap

136.5M

Sector

Finance

ML Signal

N/A

Logo Polaryx Therapeutics Inc. Common Stock

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$1.76

Market Cap

112.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MHF
PLYX
Founded
1988
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
136.5M
112.7M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
MHF
PLYX
Price
$6.42
$1.76
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $7.50
AVG Volume (30 Days)
★ 119.6K
24.1K
Earning Date
01-01-0001
11-14-2026
Dividend Yield
★ 4.29%
N/A
EPS Growth
N/A
★ 77.53
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.84
$1.76
52 Week High
$7.22
$10.93

Technical Indicators

Market Signals
Indicator
MHF
PLYX
Relative Strength Index (RSI) 50.17 33.92
Support Level $5.84 N/A
Resistance Level $7.04 $2.18
Average True Range (ATR) 0.17 0.11
MACD 0.01 -0.01
Stochastic Oscillator 54.92 13.00

Price Performance

Historical Comparison
MHF
PLYX

About MHF Western Asset Municipal High Income Fund Inc.

Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: